Asphalion Managing Director, Núria Romero, and Lidia Cánovas, General Manager, Regulatory Affairs, are attending the 18th Biosimilar Medicines Conference by MFE that is taking place in Brussels. At the Conference, speakers and panellists are exploring how to turn the Pharmaceutical Strategy with the aim to ensure better access and affordability into concrete biosimilar medicine policy measures.
Yannis Natsis Director of the European Social Insurance Platform (ESIP), has stated that solidarity and social protection have been key for having made Europe Different and that developing biosimilars is a question of solidarity and sustainability.
Also, Andrzej Rys Director for Health Systems and Products in the Directorate General for Health and Food Safety at the European Commission said that, in order to be competent with the 120 biologic molecules and to get these to become biosimilars, regulatory and legal changes are needed.
For further information you can check the conference website: https://www.medicinesforeurope.com/events/bios22/
If you require any other information, you can contact us at: firstname.lastname@example.org